Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis

Clicks: 449
ID: 115475
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #3 of 9 articles by views in journal of crohn's & colitis

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Vedolizumab was associated with significantly higher deep remission rates than placebo at Week 52, regardless of deep remission definition [NCT00783718].
Reference Key
wj2019journaldeep Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sandborn WJ;Colombel JF;Panaccione R;Dulai PS;Rosario M;Cao C;Barocas M;Lasch K;;
Journal journal of crohn's & colitis
Year 2019
DOI
DOI not found
URL
https://www.pubmed.gov/30285104/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine adult female male adolescent aged middle aged young adult Randomized Controlled Trial Antibodies Monoclonal severity of illness index Humanized / therapeutic use* Colitis Ulcerative / drug therapy* Gastrointestinal Agents / therapeutic use* remission induction / methods ulcerative / pathology pmid:30285104 pmc6357899 doi:10.1093/ecco-jcc/jjy149 william j sandborn jean-frédéric colombel karen lasch

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.